Foghorn sounds another warning about the class of ‘20

Full clinical hold on Foghorn Therapeutics’ lead asset, a move that yesterday spurred a 25% share price decline, marks another disappointing outcome for the IPO class of 2020. The year was marked by Covid lockdowns and an apparently insatiable investor appetite for biotech.